Ruben Donis Influenza Division, Centers for Disease Control and Prevention, USA
2 protocols

George Gao CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, China
2 protocols

Cheng-Feng Qin Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, China
2 protocols

SeoungSuh Hong Biotechnology Research Institute, Celltrion, Inc., South Korea
2 protocols

Shin Jae Chang
  • Biotechnology Research Institute, Celltrion, Inc., South Korea
  • 2 Author merit


Ph.D., School of Agriculture and Food Systems, The University of Melbourne, Australia, 2004

Current position

Vice president, Biotechnology Research Institute, Celltrion, Inc., South Korea


Selected papers (4 of 17)

  1. Wu, Y., Cho, M., Shore, D., Song, M., Choi, J., Jiang, T., Deng, Y. Q., Bourgeois, M., Almli, L., Yang, H., Chen, L. M., Shi, Y., Qi, J., Li, A., Yi, K. S., Chang, M., Bae, J. S., Lee, H., Shin, J., Stevens, J., Hong, S., Qin, C. F., Gao, G. F., Chang, S. J. and Donis, R. O. (2015). A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun 6: 7708.
  2. Jung, S. K., Lee, K. H., Jeon, J. W., Lee, J. W., Kwon, B. O., Kim, Y. J., Bae, J. S., Kim, D. I., Lee, S. Y. and Chang, S. J. (2014). Physicochemical characterization of Remsima. MAbs 6(5): 1163-1177.
  3. Lee, H. J., Chang, M., Kim, J. M., Hong, H., Maeng, K., Koo, J., Chang, S. and Cho, M. S. (2013). Application of a new human cell line, F2N78, in the transient and stable production of recombinant therapeutics. Biotechnol Prog 29(2): 432-440.
  4. Lee, S. Y., Kwon, Y. B., Cho, J. M., Park, K. H., Chang, S. J. and Kim, D. (2012). Effect of process change from perfusion to fed-batch on product comparability for biosimilar monoclonal antibody. Process Biochem 47(9): 1411-1418.

Patents (2 of 54)

  1. Chang, S. J., Kwon, K. S., Yi, K. S., Lee, H. J., Jeon, J. W., Jun, H. K. and Chang, M. S. Binding molecules having influenza A virus-neutralizing activity produced from human B cells. US Patent 14/348,284 assigned to Celltrion, Inc.
  2. Chang, S. J., Kim, J. M., Yi, K. S. and Jun, H. K. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses. US Patent 13/583,529 assigned to Celltrion, Inc.
2 Protocols published
Micro Neutralization (MN) Assay of Influenza Viruses with Monoclonal Antibodies
The human monoclonal antibodies generated from single human B cells were tested to characterize their ability to neutralize virus infectivity. The microneutralization assay is a highly sensitive and specific assay for detecting virus-specific ...
Haemagglutination Inhibition (HI) Assay of Influenza Viruses with Monoclonal Antibodies
Heamagglutination is inhibited when antibodies are present because antibodies to influenza virus will prevent attachment of the virus to red blood cells. The highest dilution of antibody that prevents hemagglutination is called the HI titer. The ...